CSOWM EXAM PREPQUESTIONSWITH v v v v
CORRECT ANSWERS 2025 v v v
Physical Activity for Children/Adolescents with DM (1 & 2) & Pre-DM - CORRECT ANSWER -
v v v v v v v v v v v v v v
At least 60 min/day of moderate to vigorous aerobic activity
v v v v v v v v v
vigorous muscle strengthening and bone strengthening activity at least 3 days per week
v v v v v v v v v v v v
Physical Activity for Adults with DM - CORRECT ANSWER -
v v v v v v v v v
150 min of moderate to vigorous aerobic activity weekly (over at least 3 days)
v v v v v v v v v v v v v
no more than 2 consecutive days w/o activity
v v v v v v v
75 min of vigorous aerobic activity weekly (if appropriate)
v v v v v v v v
2-3 weekly sessions of resistance exercise on non consecutive days
v v v v v v v v v
all adults should decrease sedentary time (interrupt every 30 min for BG benefit)
v v v v v v v v v v v v
flexibility & balance training recommended 2-3 times weekly for older adults with DM
v v v v v v v v v v v v
Potential contraindications for diabetes and exercise - CORRECT ANSWER -
v v v v v v v v v
Retinopathy (risk of vitreous hemorrhage or retinal detachment)
v v v v v v v v
Peripheral neuropathy (exam feet, wear protection)
v v v v v
Autonomic neuropathy (thorough cardiac eval) v v v v
Diabetic kidney disease (acutely increase urinate albumin excretion) , however no specific exercise rest
v v v v v v v v v v v v v
rictions needed.
v v
,DM and Psychosocial Care - CORRECT ANSWER -Should be integrated with a pt-
v v v v v v v v v v v v
centered approach & provided to all people diagnosed
v v v v v v v v
may include attitudes: expectations with meds and outcomes, affect or mood, QOL, resources like fina
v v v v v v v v v v v v v v
ncial, social, emotional, and psychiatric history
v v v v v v
Critical times to evaluate DSMES - CORRECT ANSWER -1. At diagnosis
v v v v v v v v v v
2. Annually
3. When complications arise v v
4. When transitions in care occur v v v v
Behavior Management for Diabetics - CORRECT ANSWER -DSMES
v v v v v v v
v MNT
Physical Activity v
Smoking cessation v
v Psychosocial care v
Pharmacotherapy for type 2 DM - CORRECT ANSWER -Metformin initially (low cost) v v v v v v v v v v v
Early insulin if evidence of catabolism, hyperglycemia, & A1c > 10%
v v v v v v v v v v
SGLT-2 inhibitors or GLP-1 agonist in patients with CVD, kidney dx, or heart failure
v v v v v v v v v v v v v
DPP-4 inhibitors - CORRECT ANSWER -weight neutral type II DM medication ends
v v v v v v v v v v v
v in -gliptin
v
(Januvia)
Better GI tolerability over Metformin
v v v v
Type II DM Meds that cause weight gain - CORRECT ANSWER -Thiazolidinediones (low cost)
v v v v v v v v v v v v v
,Sulfonylureas (Glyburide, Glipizide, Glimepiride) (low cost) v v v v v
v Insulin
GLP-1 Agonists - CORRECT ANSWER -Liraglutide (Victoza, Saxenda)
v v v v v v v
v Semaglutide (Ozempic, Wegovy) v v
Exenatide
Dulaglutide (Trulicity) v
Injections that affect POMC neurons and cause satiety v v v v v v v
SGLT2 inhibitors - CORRECT ANSWER -Canagliflozin (Invokana)
v v v v v v
v Dapagliflozin (Farxiga) v
Empagliflozin (Jardiance) v
prevents reabsorptions of glucose as well as water in the renal tubules
v v v v v v v v v v v
Assessment of Obesity Management in Type II DM - CORRECT ANSWER - v v v v v v v v v v v
Annual BMI calculations (more frequently if necessary)
v v v v v v v
Inpatient eval may be necessary if deterioration of medical status is associated with significant weight gain
v v v v v v v v v v v v v v v
or loss (medication use, food intake, glycemic status)
v v v v v v v v
For pt's with high weight-related stress, special accommodations should be made to ensure privacy
v v v v v v v v v v v v v
Obesity Management in Type II DM (short-term) - CORRECT ANSWER -
v v v v v v v v v v
Diet, PA, and BT designed to achieve and maintain >/= 5% weight loss (3- 5%
v v v v v v v v v v v v v v
is minimum for any benefit)
v v v v v
>/= 16 sessions in 6 months
v v v v v
Achieve a 500-750 kcal deficit (individualized meal planning)
v v v v v v v
, Individual or group settings v v v
Very low-calorie diets (</= 800 kcal) prescribed only to carefully selected patients
v v v v v v v v v v v
Obesity Management in Type II DM (long-term) - CORRECT ANSWER - For
v v v v v v v v v v v
>/= 1 year weight maintenance:
v v v v v
- minimum monthly contact v v
- 200-300 min/wk of physical activity v v v v
-self-monitoring
Look AHEAD Trial - CORRECT ANSWER -Assessed long-
v v v v v v v
term health consequences of intentional wt loss. Showed feasibility of achievingGand maintaining long-
v v v v v v v v v v v v
term (13.5 years) weight loss in patients with type II DM.
v v v v v v v v v v v
Participants randomly assigned to the intensive lifestyle group achieved equivalent risk factor control b ut
v v v v v v v v v v v v v v
required fewer glucose-, blood pressure-, and lipid-
v v v v v v v
lowering meds than those randomly assigned to standard care. Other improvements included increase d
v v v v v v v v v v v v v
mobility, physical and sexual functioning, and health-related QoL
v v v v v v v v
(did NOT show reduced CVD events in diabetics & overweight/obesity)
v v v v v v v v v
DM meds that can promote weight loss - CORRECT ANSWER -Metformin
v v v v v v v v v v
v Alpha-glucosidase inhibitors v
SGLT-2 inhibitors v
GLP-1 agonsits
v v
Amylin mimetics (Pramlintide) v v
Metabolic Surgery for Type II DM - CORRECT ANSWER -BMI >/= 35 (Asian Americans >/= 32.5)
v v v v v v v v v v v v v v v
Pts who do not achieve durable weight loss and improvement in comorbidities with nonsurgical metho ds
v v v v v v v v v v v v v v v
CORRECT ANSWERS 2025 v v v
Physical Activity for Children/Adolescents with DM (1 & 2) & Pre-DM - CORRECT ANSWER -
v v v v v v v v v v v v v v
At least 60 min/day of moderate to vigorous aerobic activity
v v v v v v v v v
vigorous muscle strengthening and bone strengthening activity at least 3 days per week
v v v v v v v v v v v v
Physical Activity for Adults with DM - CORRECT ANSWER -
v v v v v v v v v
150 min of moderate to vigorous aerobic activity weekly (over at least 3 days)
v v v v v v v v v v v v v
no more than 2 consecutive days w/o activity
v v v v v v v
75 min of vigorous aerobic activity weekly (if appropriate)
v v v v v v v v
2-3 weekly sessions of resistance exercise on non consecutive days
v v v v v v v v v
all adults should decrease sedentary time (interrupt every 30 min for BG benefit)
v v v v v v v v v v v v
flexibility & balance training recommended 2-3 times weekly for older adults with DM
v v v v v v v v v v v v
Potential contraindications for diabetes and exercise - CORRECT ANSWER -
v v v v v v v v v
Retinopathy (risk of vitreous hemorrhage or retinal detachment)
v v v v v v v v
Peripheral neuropathy (exam feet, wear protection)
v v v v v
Autonomic neuropathy (thorough cardiac eval) v v v v
Diabetic kidney disease (acutely increase urinate albumin excretion) , however no specific exercise rest
v v v v v v v v v v v v v
rictions needed.
v v
,DM and Psychosocial Care - CORRECT ANSWER -Should be integrated with a pt-
v v v v v v v v v v v v
centered approach & provided to all people diagnosed
v v v v v v v v
may include attitudes: expectations with meds and outcomes, affect or mood, QOL, resources like fina
v v v v v v v v v v v v v v
ncial, social, emotional, and psychiatric history
v v v v v v
Critical times to evaluate DSMES - CORRECT ANSWER -1. At diagnosis
v v v v v v v v v v
2. Annually
3. When complications arise v v
4. When transitions in care occur v v v v
Behavior Management for Diabetics - CORRECT ANSWER -DSMES
v v v v v v v
v MNT
Physical Activity v
Smoking cessation v
v Psychosocial care v
Pharmacotherapy for type 2 DM - CORRECT ANSWER -Metformin initially (low cost) v v v v v v v v v v v
Early insulin if evidence of catabolism, hyperglycemia, & A1c > 10%
v v v v v v v v v v
SGLT-2 inhibitors or GLP-1 agonist in patients with CVD, kidney dx, or heart failure
v v v v v v v v v v v v v
DPP-4 inhibitors - CORRECT ANSWER -weight neutral type II DM medication ends
v v v v v v v v v v v
v in -gliptin
v
(Januvia)
Better GI tolerability over Metformin
v v v v
Type II DM Meds that cause weight gain - CORRECT ANSWER -Thiazolidinediones (low cost)
v v v v v v v v v v v v v
,Sulfonylureas (Glyburide, Glipizide, Glimepiride) (low cost) v v v v v
v Insulin
GLP-1 Agonists - CORRECT ANSWER -Liraglutide (Victoza, Saxenda)
v v v v v v v
v Semaglutide (Ozempic, Wegovy) v v
Exenatide
Dulaglutide (Trulicity) v
Injections that affect POMC neurons and cause satiety v v v v v v v
SGLT2 inhibitors - CORRECT ANSWER -Canagliflozin (Invokana)
v v v v v v
v Dapagliflozin (Farxiga) v
Empagliflozin (Jardiance) v
prevents reabsorptions of glucose as well as water in the renal tubules
v v v v v v v v v v v
Assessment of Obesity Management in Type II DM - CORRECT ANSWER - v v v v v v v v v v v
Annual BMI calculations (more frequently if necessary)
v v v v v v v
Inpatient eval may be necessary if deterioration of medical status is associated with significant weight gain
v v v v v v v v v v v v v v v
or loss (medication use, food intake, glycemic status)
v v v v v v v v
For pt's with high weight-related stress, special accommodations should be made to ensure privacy
v v v v v v v v v v v v v
Obesity Management in Type II DM (short-term) - CORRECT ANSWER -
v v v v v v v v v v
Diet, PA, and BT designed to achieve and maintain >/= 5% weight loss (3- 5%
v v v v v v v v v v v v v v
is minimum for any benefit)
v v v v v
>/= 16 sessions in 6 months
v v v v v
Achieve a 500-750 kcal deficit (individualized meal planning)
v v v v v v v
, Individual or group settings v v v
Very low-calorie diets (</= 800 kcal) prescribed only to carefully selected patients
v v v v v v v v v v v
Obesity Management in Type II DM (long-term) - CORRECT ANSWER - For
v v v v v v v v v v v
>/= 1 year weight maintenance:
v v v v v
- minimum monthly contact v v
- 200-300 min/wk of physical activity v v v v
-self-monitoring
Look AHEAD Trial - CORRECT ANSWER -Assessed long-
v v v v v v v
term health consequences of intentional wt loss. Showed feasibility of achievingGand maintaining long-
v v v v v v v v v v v v
term (13.5 years) weight loss in patients with type II DM.
v v v v v v v v v v v
Participants randomly assigned to the intensive lifestyle group achieved equivalent risk factor control b ut
v v v v v v v v v v v v v v
required fewer glucose-, blood pressure-, and lipid-
v v v v v v v
lowering meds than those randomly assigned to standard care. Other improvements included increase d
v v v v v v v v v v v v v
mobility, physical and sexual functioning, and health-related QoL
v v v v v v v v
(did NOT show reduced CVD events in diabetics & overweight/obesity)
v v v v v v v v v
DM meds that can promote weight loss - CORRECT ANSWER -Metformin
v v v v v v v v v v
v Alpha-glucosidase inhibitors v
SGLT-2 inhibitors v
GLP-1 agonsits
v v
Amylin mimetics (Pramlintide) v v
Metabolic Surgery for Type II DM - CORRECT ANSWER -BMI >/= 35 (Asian Americans >/= 32.5)
v v v v v v v v v v v v v v v
Pts who do not achieve durable weight loss and improvement in comorbidities with nonsurgical metho ds
v v v v v v v v v v v v v v v